Equivalent dynamic human brain NK1-receptor occupancy following single-dose i.v. fosaprepitant vs. oral aprepitant as assessed by PET imaging

Clinical Pharmacology and Therapeutics

Volumn 92, Issue 2, 2012, Pages 243-250

  Van Laere, K ^a   De Hoon, J ^a   Bormans, G ^b   Koole, M ^a   Derdelinckx, I ^a   De Lepeleire, I ^c   Declercq, R ^c   Sanabria Bohorquez, S M ^d   Hamill, T ^d   Mozley, P D ^d   Tatosian, D ^d   Xie, W ^d   Liu, Y ^d   Liu, F ^d   Zappacosta, P ^d   Mahon, C ^d   Butterfield, K L ^d   Rosen, L B ^d   Murphy, M G ^d   Hargreaves, R J ^d   Wagner, J A ^d   Shadle, C R ^d   more..

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b UNIVERSITY OF LEUVEN   (Belgium)

^c UCB PHARMA   (Belgium)

^d MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APREPITANT; DEXAMETHASONE; FLUORINE 18; FOSAPREPITANT; MK 0999; ONDANSETRON; RADIOPHARMACEUTICAL AGENT; TACHYKININ RECEPTOR; TYPE 1 NEUROKININ RECEPTOR; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BIOEQUIVALENCE; BLOOD LEVEL; BRAIN RADIOGRAPHY; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG SCREENING; GASTROESOPHAGEAL REFLUX; HICCUP; HUMAN; MALE; NORMAL HUMAN; OPEN STUDY; PARALLEL DESIGN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RECEPTOR OCCUPANCY; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADULT; ANTIEMETICS; ANTINEOPLASTIC AGENTS; BRAIN; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; MORPHOLINES; NAUSEA; POSITRON-EMISSION TOMOGRAPHY; PRODRUGS; RECEPTORS, NEUROKININ-1; THERAPEUTIC EQUIVALENCY; VOMITING; YOUNG ADULT;

EID: 84864133293     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2012.62     Document Type: Article

References (17)

1. Hargreaves, R. et al. Development of aprepitant, the first neurokinin-1 receptor antagonist for the prevention of chemotherapy-induced nausea and vomiting. Ann. N. Y. Acad. Sci. 1222, 40-48 (2011).
2. Langford, P. & Chrisp, P. Fosaprepitant and aprepitant: an update of the evidence for their place in the prevention of chemotherapy-induced nausea and vomiting. Core Evid. 5, 77-90 (2010).
3. Navari, R.M. Fosaprepitant: a neurokinin-1 receptor antagonist for the prevention of chemotherapy-induced nausea and vomiting. Expert Rev. Anticancer Ther. 8, 1733-1742 (2008).
4. Lasseter, K.C. et al. Tolerability of fosaprepitant and bioequivalency to aprepitant in healthy subjects. J. Clin. Pharmacol. 47, 834-840 (2007).
5. G runberg, S. et al. Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with cisplatin therapy: randomized, double-blind study protocol-EASE. J. Clin. Oncol. 29, 1495-1501 (2011).
6. Hietala, J. et al. Visualization and quantification of neurokinin-1 (NK1) receptors in the human brain. Mol. Imaging Biol. 7, 262-272 (2005).
7. Bergström, M. et al. Human positron emission tomography studies of brain neurokinin 1 receptor occupancy by aprepitant. Biol. Psychiatry 55, 1007-1012 (2004). (Pubitemid 38581916)
8. Chawla, S.P. et al. Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting. Cancer 97, 2290-2300 (2003). (Pubitemid 36444075)
9. Hargreaves, R. Imaging substance P receptors (NK1) in the living human brain using positron emission tomography. J. Clin. Psychiatry 63 (suppl. 11), 18-24 (2002). (Pubitemid 35435004)
10. A apro, M.S. & Walko, C.M. Aprepitant: drug-drug interactions in perspective. Ann. Oncol. 21, 2316-2323 (2010).
11. Nyman, M.J. et al. Gender and age affect NK1 receptors in the human brain- A positron emission tomography study with 18FSPA-RQ. Int. J. Neuropsychopharmacol. 10, 219-229 (2007).
12. Engman, J. et al. Age, sex and NK1 receptors in the human brain- A positron emission tomography study with (11)CGR205171. Eur. Neuropsychopharmacol. (2012). e-pub ahead of print 4 January 2012.
13. T onkens, R.M. Breaking into clinical research. Physician Exec. 31, 48-52 (2005).
14. S prague, D.R. et al. Human biodistribution and radiation dosimetry of the tachykinin NK1 antagonist radioligand 18FSPA-RQ: comparison of thin-slice, bisected, and 2-dimensional planar image analysis. J. Nucl. Med. 48, 100-107 (2007). (Pubitemid 47555382)
15. S anabria, S. et al. Simplified method for NK1 receptor quantification in human brain. Mol. Imaging. Biol. 8, 2 (2006).
16. Yasuno, F. et al. PET imaging of neurokinin-1 receptors with (18)FSPA-RQ in human subjects: assessment of reference tissue models and their test-retest reproducibility. Synapse 61, 242-251 (2007).
17. Innis, R.B. et al. Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J. Cereb. Blood Flow Metab. 27, 1533-1539 (2007). (Pubitemid 47301451)